Last update Nov. 8, 2023
Very Low Risk
Dexibuprofen is a pharmacologically active enantiomer of the racemic ibuprofen used to treat pain and inflammation. Pharmacokinetically and clinically it behaves like ibuprofen itself (Yoon 2008, Sádaba 2006). Oral administration in three daily doses.
On latest update no published data about breastfeeding were found.
Its high binding to plasma proteins makes it unlikely to be excreted in breast milk in significant quantities.
As it is an enantiomer of ibuprofen, with similar pharmacokinetic characteristics, it is considered to have similar compatibility with breastfeeding.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM